Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Izzy who wrote (5320)	9/18/1998 10:00:00 AM
From: Joe E.	Respond to of 6136

Dupont says FDA oks one-a-day HIV drug WILMINGTON, Del., Sept 18 (Reuters) - DuPont Pharmaceuticals (DD - news) said on Friday the U.S. Food and Drug Administration approved Sustiva, a one-pill-a-day drug to treat the virus that causes AIDS. Although in recent years new HIV drugs have helped reduce the disease from a certain death sentence into a chronic condition, the number of pills patients have to swallow daily has been considered a major obstacle to treatment.

To: Izzy who wrote (5320)	9/18/1998 10:02:00 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 6136

DMP-266 approved. I'm surprised that the jerk knee jerk has been so restrained thus far...... down 1/8 on 95K shares. Flash from the past....... Monday June 29, 8:05 am Eastern Time Company Press Release SOURCE: Agouron Pharmaceuticals, Inc. Agouron Acquires New Anti-HIV Drug from Shionogi LA JOLLA, Calif., June 29 /PRNewswire/ -- Agouron Pharmaceuticals, Inc. (Nasdaq: AGPH - news) today announced it will develop and commercialize S-1153, a second generation non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV infection. Discovered by Shionogi & Co., Ltd., Osaka, Japan, S-1153 is currently the subject of several clinical trials evaluating its dose and its concomitant use with other antiretroviral treatments. S-1153 is of high clinical interest because it is more potent in vitro than other NNRTIs such as nevirapine (Viramune(R)) and delavirdine (Rescriptor(R)) and because S-1153 is fully active in vitro against HIV containing the most common genetic mutation associated with resistance to other NNRTIs including efavirenz (Sustiva(TM)). (snip)